Literature DB >> 16436656

Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.

Peter Fickert1, Andrea Fuchsbichler, Hanns-Ulrich Marschall, Martin Wagner, Gernot Zollner, Robert Krause, Kurt Zatloukal, Hartmut Jaeschke, Helmut Denk, Michael Trauner.   

Abstract

We determined the mechanisms of hepatobiliary injury in the lithocholic acid (LCA)-fed mouse, an increasingly used model of cholestatic liver injury. Swiss albino mice received control diet or 1% (w/w) LCA diet (for 1, 2, and 4 days), followed by assessment of liver morphology and ultrastructure, tight junctions, markers of fibrosis and key proteins of hepatobiliary function, and bile flow and composition. As expected LCA feeding led to bile infarcts, which were followed by a destructive cholangitis with activation and proliferation of periductal myofibroblasts. At the ultrastructural level, small bile ducts were frequently obstructed by crystals. Biliary-excreted fluorescence-labeled ursodeoxycholic acid accumulated in bile infarcts, whereas most infarcts did not stain with India ink injected into the common bile duct; both findings are indicative of partial biliary obstruction. Expression of the main basolateral bile acid uptake proteins (sodium-taurocholate cotransporter and organic anion-transporting polypeptide 1) was reduced, the canalicular transporters bile salt export pump and multidrug-related protein 2 were preserved, and the basolateral transporter multidrug-related protein 3 and the detoxifying enzyme sulfotransferase 2a1 were induced. Thus, we demonstrate that LCA feeding in mice leads to segmental bile duct obstruction, destructive cholangitis, periductal fibrosis, and an adaptive transporter and metabolic enzyme response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436656      PMCID: PMC1606500          DOI: 10.2353/ajpath.2006.050404

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.

Authors:  P Fickert; G Zollner; A Fuchsbichler; C Stumptner; C Pojer; R Zenz; F Lammert; B Stieger; P J Meier; K Zatloukal; H Denk; M Trauner
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 2.  The continuing importance of bile acids in liver and intestinal disease.

Authors:  A F Hofmann
Journal:  Arch Intern Med       Date:  1999 Dec 13-27

3.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

Authors:  W Xie; A Radominska-Pandya; Y Shi; C M Simon; M C Nelson; E S Ong; D J Waxman; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity.

Authors:  J L Staudinger; B Goodwin; S A Jones; D Hawkins-Brown; K I MacKenzie; A LaTour; Y Liu; C D Klaassen; K K Brown; J Reinhard; T M Willson; B H Koller; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Production of bile duct hyperplasia and gallstones by lithocholic acid.

Authors:  R H Palmer; Z Ruban
Journal:  J Clin Invest       Date:  1966-08       Impact factor: 14.808

6.  Scanning electron microscopy of the rat liver. Studies of the effect of taurolithocholate and other models of cholestasis.

Authors:  T J Layden; J L Boyer
Journal:  Gastroenterology       Date:  1975-09       Impact factor: 22.682

7.  Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.

Authors:  U Beuers; M Bilzer; A Chittattu; G A Kullak-Ublick; D Keppler; G Paumgartner; F Dombrowski
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

8.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

9.  Subcellular pathology of rat liver in cholestasis and choleresis induced by bile salts. 1. Effects of lithocholic, 3beta-hydroxy-5-cholenoic, cholic, and dehydrocholic acids.

Authors:  K Miyai; A L Richardson; W Mayr; N B Javitt
Journal:  Lab Invest       Date:  1977-03       Impact factor: 5.662

10.  Bile acid sulfates. II. Formation, metabolism, and excretion of lithocholic acid sulfates in the rat.

Authors:  R H Palmer
Journal:  J Lipid Res       Date:  1971-11       Impact factor: 5.922

View more
  59 in total

1.  High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

Authors:  M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2011-09-29       Impact factor: 8.171

2.  A comparative study of the sulfation of bile acids and a bile alcohol by the Zebra danio (Danio rerio) and human cytosolic sulfotransferases (SULTs).

Authors:  Katsuhisa Kurogi; Matthew D Krasowski; Elisha Injeti; Ming-Yih Liu; Frederick E Williams; Yoichi Sakakibara; Masahito Suiko; Ming-Cheh Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2011-08-04       Impact factor: 4.292

3.  Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Methods Mol Biol       Date:  2015

4.  Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Authors:  James J Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2018-11-30       Impact factor: 3.922

5.  The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway.

Authors:  Dong-ke Yu; Cai-xia Zhang; Shuang-shuang Zhao; Sheng-hua Zhang; Hao Zhang; Shi-ying Cai; Rong-guang Shao; Hong-wei He
Journal:  Acta Pharmacol Sin       Date:  2015-03-16       Impact factor: 6.150

6.  Participation of nuclear factor (erythroid 2-related), factor 2 in ameliorating lithocholic acid-induced cholestatic liver injury in mice.

Authors:  K P Tan; G A Wood; M Yang; S Ito
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 7.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 8.  Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Authors:  Michael Trauner; Peter Fickert; Emina Halilbasic; Tarek Moustafa
Journal:  Wien Med Wochenschr       Date:  2008

9.  Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis.

Authors:  Carol J Soroka; Albert Mennone; Lee R Hagey; Nazzareno Ballatori; James L Boyer
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

10.  Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge.

Authors:  Joo-Youn Cho; Tsutomu Matsubara; Dong Wook Kang; Sung-Hoon Ahn; Kristopher W Krausz; Jeffrey R Idle; Hans Luecke; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2009-11-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.